What Biocompatible Means for Your Filler: The ISO 10993 Testing Behind Dermal Injectables

When patients research dermal fillers, biostimulators, or lifting threads, they are flooded with clinical terminology and marketing claims. Clinic websites promise that hyaluronic acid (HA) fillers are "natural and fully dissolvable," that poly-L-lactic acid (PLLA) biostimulators are "completely biocompatible," and that polydioxanone (PDO) threads are "sterile and safe."

However, in the era of online shopping and unregulated medical spas, there has been a dangerous surge in off-brand, compounded, and counterfeit injectables. Some providers purchase cheap, imported dermal fillers online, claiming they are "essentially the same" as FDA-approved brands.

For patients and injectors looking for a direct answer: "Biocompatible" is not a marketing term—it is a standardized regulatory gate defined by the ISO 10993 standard. Any material implanted into the human body, including dermal fillers, biostimulators (Sculptra, Radiesse), and PDO threads, must pass an exhaustive battery of biological safety evaluations—including cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), irritation (ISO 10993-23), chemical characterization (ISO 10993-18), and long-term local tissue response/implantation (ISO 10993-6). Off-brand, compounded, or counterfeit injectables skip this multi-million dollar testing suite, which is the direct scientific explanation for why they cause severe delayed adverse events—such as chronic inflammatory nodules, foreign-body granulomas, and tissue necrosis—that legitimate, tested products do not. Undergoing treatment with an untested material is a biological gamble.

This comprehensive reference breaks down the material science behind biocompatibility, maps the specific ISO 10993 testing endpoints to the adverse events patients fear, analyzes the impact of contact duration, details the latest 2026 standard updates, and provides a framework to protect yourself from untested injectables.

---

What Biocompatibility Actually Means: The ISO 10993-1 Definition

The international standard ISO 10993-1 defines biocompatibility as:

"The ability of a medical device or material to perform with an appropriate host response in a specific application."

This definition contains two load-bearing concepts:

1. Appropriate Host Response: The material must not trigger an adverse local or systemic reaction. It should not kill surrounding cells (cytotoxicity), cause an allergic reaction (sensitization), trigger persistent inflammation (irritation), or poison the patient (systemic toxicity).
2. Specific Application: A material that is biocompatible in one area of the body may be highly toxic in another. For example, titanium is highly biocompatible when anchored into bone as a dental implant, but titanium dust in the lungs is highly toxic. In the context of aesthetics, a polymer that is safe when applied to intact skin can cause severe foreign-body reactions when injected into the deep dermis or subcutaneous tissue.

Biocompatibility is evaluated within a structured risk-management framework. Before any dermal filler or biostimulator is cleared or approved by the FDA, the manufacturer must establish a biological evaluation plan (BEP) to identify risks, execute specific laboratory and animal tests, and compile a biological evaluation report (BER) by qualified toxicologists.

To understand how this material science fits into the commercial market, read our guide on who owns the FDA-approved filler market.

---

The Biological Cascade: The Foreign Body Response (FBR) Explained

When a dermal filler or lifting thread is introduced into subcutaneous or dermal tissue, the body initiates a highly coordinated cellular defense mechanism known as the Foreign Body Response (FBR). Understanding this biological cascade explains why biocompatibility testing is so load-bearing:

[Injection of Material] ───> [Protein Adsorption] ───> [Neutrophil Influx]
                                                                │
                                                                ▼
[Fibrous Encapsulation] <─── [Macrophage Fusion] <─── [Macrophage Recruitment]
(Granuloma or Soft Sleeve)     (Foreign Body Giant Cells)

1. Protein Adsorption (Seconds to Minutes): Immediately upon injection, the material's surface is coated with blood proteins and interstitial fluid components (albumin, fibrinogen, fibronectin, and immunoglobulins). The physical and chemical profile of the material—its surface charge, hydrophobicity, and micro-texture—dictates which proteins adsorb and in what conformation.
2. Acute Inflammation and Neutrophil Infiltration (Hours to Days): The adsorbed proteins trigger the complement cascade, attracting neutrophils (white blood cells) to the site. Neutrophils attempt to phagocytose (engulf) the material. Because the filler particles or thread surfaces are far larger than a single cell, neutrophils release reactive oxygen species (ROS) and proteolytic enzymes in a process termed "frustrated phagocytosis."
3. Macrophage Recruitment and Activation (Days to Weeks): As neutrophils die, chemical signals attract monocytes, which differentiate into macrophages. Macrophages adhere to the protein-coated surface of the filler or thread. In a biocompatible material, macrophages transition from a pro-inflammatory (M1) phenotype to a wound-healing (M2) phenotype, signaling local fibroblasts to start tissue repair.
4. Macrophage Fusion into Foreign Body Giant Cells (FBGCs) (Weeks): If the material is recognized as highly foreign or contains toxic chemical residues, the macrophages remain activated in the M1 state. To increase their phagocytic capacity, individual macrophages fuse their cell membranes to form large, multinucleated Foreign Body Giant Cells (FBGCs).
5. Fibroblast Recruitment and Fibrous Encapsulation (Weeks to Months): Persistent signals from FBGCs recruit fibroblasts, which deposit a dense matrix of collagen fibers around the material.
   • The Biocompatible Outcome: A thin, soft, well-vascularized collagen sleeve forms around the filler, allowing it to integrate smoothly into the surrounding facial movement.
   • The Non-Biocompatible Outcome (Granuloma): If the material continues to leach impurities or is toxic, the fibrous capsule becomes thick, dense, and avascular. The immune system continuously builds layers of collagen, resulting in a hard, palpable, and clinically visible inflammatory nodule—a foreign-body granuloma.

---

The ISO 10993 Endpoint Matrix: Mapped to the Complications You Fear

When an untested filler is injected into your face, it doesn't just sit there. Your immune system immediately inspects the material. If the material fails biocompatibility testing, it will trigger the exact complications patients fear.

The table below maps the primary ISO 10993 testing endpoints to their real-world clinical complications:

1. Cytotoxicity (ISO 10993-5) and Acute Tissue Reactions

In a cytotoxicity test, cells (typically fibroblasts) are cultured in a laboratory and exposed directly to the filler material or an extract of the material. If more than 30% of the cells die or show structural malformations within 24 to 72 hours, the material is considered cytotoxic and fails the standard.

When a counterfeit or compounded filler uses low-grade hyaluronic acid or contains residues of industrial solvents, it can cause acute cell death upon injection. This manifests as sterile abscesses—painful, pus-filled pockets that occur without a bacterial infection.

2. Sensitization (ISO 10993-10) and Delayed Allergic Nodules

Sensitization tests (typically the guinea pig maximization test or the murine local lymph node assay) evaluate whether repeated exposure to a material causes an allergic immune response.

Legitimate fillers undergo rigorous purification to remove proteins and bacterial endotoxins left over from fermentation. In contrast, unpurified, off-brand fillers contain high levels of bacterial proteins. While the initial injection may appear fine, the patient's immune system slowly becomes sensitized. Weeks or months later, the body mounts a massive T-cell response, resulting in delayed-onset allergic nodules across all injection sites.

To learn how to clinically manage these allergic and inflammatory issues, consult our dermal filler complications and what to do clinical reference.

3. Implantation (ISO 10993-6) and Foreign-Body Granulomas

The implantation test is the most critical evaluation for long-term injectables. The material is surgically implanted into animal tissue, and the local tissue response is analyzed via histopathology at specific intervals (e.g., 1 week, 4 weeks, 12 weeks, and 26 weeks). Pathologists check for:

• Inflammatory cells (macrophages, giant cells, lymphocytes).
• Necrosis (tissue death).
• Fibrosis (scar tissue formation and capsule thickness).
• Degradation (how the material breaks down).

Every implant triggers a mild, temporary foreign-body reaction as the body attempts to wall off the material. In a biocompatible filler, this reaction is mild, stable, and resolves into a thin, soft capsule.

In an untested or contaminated material, the body cannot digest the product. Macrophages fuse together to form multinucleated giant cells, creating a persistent, hard wall of chronic inflammatory tissue known as a foreign-body granuloma. These granulomas are hard, disfiguring lumps that can grow over time and are notoriously difficult to treat, often requiring multiple rounds of intralesional steroid injections or surgical excision.

---

Why Contact Duration Decides the Testing Battery

Under ISO 10993-1, medical devices are categorized by the nature and duration of their contact with the human body. This categorization dictates which tests are mandatory:

[Contact Duration] ──────> [Regulatory Tier] ──────> [Required Testing Battery]
Limited (< 24 Hours)  ───> Low Exposure      ───> Cytotoxicity, Sensitization, Irritation
Prolonged (24h - 30d) ───> Moderate Exposure ───> Add Subacute Toxicity, Genotoxicity
Permanent (> 30 Days) ───> High Exposure     ───> Add Implantation, Chronic Toxicity, Carcinogenicity

• Limited Contact (less than 24 hours): Devices like surgical gloves or syringe needles. They require basic cytotoxicity, sensitization, and irritation testing.
• Prolonged Contact (24 hours to 30 days): Devices like temporary skin staples or external catheters. They require additional genotoxicity and subacute toxicity testing.
• Long-Term / Permanent Contact (greater than 30 days): This is the category for dermal fillers, biostimulators, and lifting threads. Because these materials are designed to reside in the face for months or years, they face the strictest testing requirements.

This duration-tier system explains why different aesthetic injectables must undergo distinct testing programs:

1. Hyaluronic Acid Fillers

Hyaluronic acid is naturally occurring, but raw HA dissolves in the body within days. To make it last, manufacturers crosslink the HA chains using chemicals like 1,4-butanediol diglycidyl ether (BDDE). To understand the chemistry of crosslinking, read our technical breakdown of the chemistry behind hyaluronic-acid fillers.

Because crosslinked HA remains in the tissue for 6 to 18 months, it is classified as a permanent implant. The FDA requires full long-term biocompatibility testing, including chemical characterization (ISO 10993-18) to prove that any free (unreacted) BDDE is below trace parts-per-million limits. Free BDDE is a known mutagen; if it is not completely washed out during manufacturing, it presents a long-term toxic risk.

2. Biostimulators (PLLA, CaHA, PMMA)

Materials like poly-L-lactic acid (Sculptra) and calcium hydroxylapatite (Radiesse) are designed to trigger a controlled inflammatory response that stimulates new collagen. To see how these compare to HA, read our clinical guide: biostimulators vs hyaluronic-acid fillers.

Because these particles degrade slowly over 2 to 3 years, they are subjected to rigorous chronic toxicity and carcinogenicity evaluations. Permanent fillers like polymethylmethacrylate (PMMA) microspheres (Bellafill) are permanent implants that never degrade. They require the absolute highest level of biocompatibility validation to ensure the body does not reject the PMMA carrier over decades. For details on permanent filler risks, read our guide on permanent PMMA filler risk.

3. Polydioxanone (PDO) & Poly-L-Lactic Acid (PLLA) Threads

Lifting threads are inserted into the subcutaneous plane to physically lift tissue and stimulate collagen before dissolving over 6 to 9 months. Even though the threads degrade, they are in contact with the body for longer than 30 days. They must be tested under ISO 10993-6 (implantation) to ensure that as the polymer degrades, the breakdown products (such as lactic acid or glycolic acid monomer residues) do not alter local tissue pH or cause sterile inflammation.

---

Technical Overview of Chemical Characterization (ISO 10993-18)

Chemical characterization is the cornerstone of modern biocompatibility evaluation. In the laboratory, toxicologists use a multi-step extraction and analysis protocol to identify any chemicals that could leach from the injectable material into the patient.

[Injectable Sample] ───> [Solvent Extraction] ───> [Analytical Instrumentation] ───> [Toxicological Risk]
                         - Polar (Water)           - GC-MS (Volatiles)                 - AET Threshold Check
                         - Semi-polar (Ethanol)    - LC-MS (Semi-volatiles)            - Impurity Clearance
                         - Non-polar (Hexane)      - ICP-MS (Heavy Metals)

1. Exhaustive Extraction: The dermal filler or thread is placed in three different solvent systems designed to mimic polar (purified water), semi-polar (isopropanol or ethanol), and non-polar (hexane) environments. These extractions are performed at elevated temperatures (e.g., 37°C or 50°C) over extended periods to force any unbound chemicals out of the polymer matrix.
2. Instrumentation Profiling: The resulting liquid extracts are analyzed using a suite of high-precision instruments:
   • Gas Chromatography-Mass Spectrometry (GC-MS): Identifies volatile organic compounds, such as residual organic solvents or low-molecular-weight crosslinker remnants.
   • Liquid Chromatography-Mass Spectrometry (LC-MS): Identifies semi-volatile and non-volatile organic compounds, including unreacted crosslinkers (like BDDE monomers) or polymer degradation products.
   • Inductively Coupled Plasma Mass Spectrometry (ICP-MS): Identifies and quantifies trace inorganic elements and heavy metals (e.g., platinum, palladium, lead, arsenic) that may have been introduced as catalysts during material synthesis.
3. Analytical Evaluation Threshold (AET): Toxicologists calculate the AET—the concentration threshold above which any single chemical impurity must be identified and evaluated for systemic toxicity, mutagenicity, or carcinogenicity. If any uncharacterized compound exceeds the AET, the material cannot be cleared for human use until the chemical's safety is proven.

Counterfeit and off-brand injectables completely avoid this chemical characterization step. The industrial-grade polymers they use frequently contain trace solvents, heavy metal catalysts, and unwashed monomers that exceed safe AET thresholds by orders of magnitude.

---

Clinical Management: Reversing Untested Materials vs. Legitimate HA Fillers

When a patient presents with a complication from an injectable, the clinician's first priority is to identify the material. The management pathway differs dramatically between biocompatibility-validated, FDA-approved injectables and unverified, off-brand alternatives:

1. Hyaluronic Acid Complications (Reversible)

• The Reconstitution and Dissolving Protocol: Legitimate HA fillers are highly responsive to hyaluronidase (an enzyme that breaks down hyaluronic acid). In the event of an impending vascular occlusion (injection into an artery) or an inflammatory nodule, clinicians inject hyaluronidase (typically reconstituted with normal saline or bacteriostatic saline) directly into the affected area.
• Dosage Parameters: Reversal requires 10 to 100 units of hyaluronidase depending on the volume and G-prime (firmness) of the filler.
• The Untested Mismatch: If a patient is injected with an off-brand filler containing uncharacterized non-HA polymers (such as liquid silicone or industrial acrylics misrepresented as HA), hyaluronidase will have zero clinical effect. The clinician may perform repeated high-dose injections (up to 500 units) to no avail, delaying necessary treatments and increasing local tissue trauma.

2. PMMA, PLLA, and Non-Reversible Complications

• Chronic Nodules and Granulomas: If a biostimulator or non-dissolvable filler triggers a foreign-body granuloma, it cannot be chemically dissolved.
• First-Line Clinical Therapy: Clinicians inject intralesional steroids (typically triamcinolone acetonide, 10mg/mL to 40mg/mL) combined with 5-fluorouracil (5-FU) directly into the center of the nodule to suppress the local immune response and slow collagen production.
• Surgical Excision: If steroid therapy fails, the only option is surgical excision. This involves incising the facial skin or mucosa to physically cut out the inflammatory tissue, presenting a high risk of facial scarring and local nerve damage.

---

Guidance for Practice Operators: Sourcing and Siting Guidelines

For aesthetic clinic owners and medical directors, maintaining strict sourcing controls is a legal, professional, and ethical mandate. Bypassing authorized supply chains is a common cause of regulatory enforcement actions and severe patient injuries.

1. Reconstitution and Preparation Protocol for Biostimulators

To minimize the risk of mechanical nodules, clinical operators must follow strict preparation guidelines for biostimulators like PLLA:

• Hydration Window: Reconstitute PLLA with Sterile Water for Injection (SWFI) at least 24 to 48 hours prior to patient injection. This allows the polymer microparticles to fully hydrate and swell, preventing clumping in the syringe.
• Dilution Ratios: Standard Sculptra reconstitution utilizes 5mL to 8mL of sterile water, often combined with 1mL to 2mL of 1% lidocaine immediately prior to injection. High dilution volumes (up to 9mL) are utilized for "hyperdilute" applications, spreading the particles thinly to stimulate collagen without concentrating the material in a single zone. For details on hyperdilute dilution math, read about hyperdilute radiesse protocols.

2. Sourcing Controls and Chain of Custody

Practice owners must audit their purchasing trail:

• Authorized Direct Portals: Purchase injectables only from manufacturer-authorized portals (e.g., Allergan Direct, Galderma Direct, Merz Aesthetics Portal).
• Verify Lot Numbers and Box Security: Every legitimate syringe features a unique lot number, expiration date, and tamper-evident seal. Charting software should scan and record these lot numbers for every patient treatment.
• Reject Parallel Imports: Parallel imports (often termed "grey-market" stock) are genuine products purchased in a foreign country (like Turkey or Poland) and resold in the US at a discount. Because these products bypass the manufacturer's temperature-controlled shipping trail, they may degrade or lose sterility, violating the chain of custody required for medical implants.

---

Freshness Hook: What the 2026 ISO 10993 Updates Change

The standards governing biocompatibility are not static. As analytical technology improves and clinical safety data accumulates, the International Organization for Standardization (ISO) updates its guidelines.

According to PureGlobal's review of the ISO 10993 and ISO 14155 standards updates, several major revisions have been introduced that establish the current state-of-the-art for biocompatibility evaluation:

1. ISO 10993-6:2026 (Implantation Updates)

The updated 2026 edition of Part 6 introduces stricter protocols for histopathological evaluation of local tissue responses.

• Annex E (Peripheral Nerve Tissue): The update adds specific guidance for testing devices that sit in close proximity to peripheral nerves, requiring histological checks to prove the material does not cause local demyelination or nerve compression. This is highly relevant for deep-dermal fillers and lifting threads placed near facial motor nerves.
• Expanded Annex G (Histopathology): Pathologists must use standardized grading matrices for chronic inflammatory markers, reducing subjective variance in determining whether an implant's local tissue response is acceptable.

2. ISO 10993-7:2026 (Ethylene Oxide Residuals)

Many medical devices and threads are sterilized using ethylene oxide (EO) gas. While highly effective, EO is a known carcinogen and mutagen.

• Stricter Tolerable Contact Limits (TCL): The 2026 update reduces the allowed daily residual limits of EO and ethylene chlorohydrin (ECH) on implantable devices, forcing manufacturers to use advanced aeration techniques to ensure trace gases are completely removed before packaging.

3. ISO 10993-1:2025 (Edition 6 Foundational Update)

As detailed in PureGlobal's analysis of the ISO 10993-1:2025 Edition 6 update, the foundational standard (published November 2025) replaces the old prescriptive "Table A1" checklist — which listed mandatory tests by device category — with a risk-based, lifecycle framework aligned with ISO 14971. Manufacturers must now justify each test from the material's actual hazards and contact characteristics rather than ticking a generic box, which sharpens the role of chemical characterization (ISO 10993-18) and material analysis in the evaluation.

4. ISO 14155:2026 (Clinical Investigation / GCP)

This standard, which governs clinical trials for medical devices, has been updated with immediate effect and no transition period. Any clinical data supporting a new filler's clearance must comply with these updated Good Clinical Practice (GCP) guidelines.

While the FDA is still reviewing these 2026 editions for formal inclusion in its Recognized Consensus Standards database, they already represent the industry state-of-the-art benchmark for global medical device development.

---

Technical Overview of Chemical Characterization (ISO 10993-18) in Practice

To execute a chemical characterization program that satisfies the U.S. FDA, testing laboratories must calculate the Analytical Evaluation Threshold (AET). The AET is a mathematically derived limit below which chemical impurities do not need to be toxicologically profiled, as their exposure level represents a negligible risk.

Calculating the AET

The AET calculation is based on the Threshold of Toxicological Concern (TTC)—a conservative exposure limit established by toxicologists for chemicals of unknown toxicity. Under ISO 10993-18, the default TTC for genotoxic (DNA-damaging) impurities is 1.5 micrograms per patient per day.

The AET is calculated using the following formula:

AET = (TTC × number of device units extracted) ÷ (extraction solvent volume × uncertainty factor)

Where:

• TTC is the Threshold of Toxicological Concern (default 1.5 µg/day for genotoxic impurities under ISO 10993-18).
• Number of device units extracted is typically a single syringe or thread.
• Extraction solvent volume is the volume of solvent used to extract the sample.
• Uncertainty factor accounts for the sensitivity variance of the analytical instruments.

If GC-MS or LC-MS chromatography detects any chemical peak exceeding the calculated AET, that compound must be identified via mass spectral libraries and toxicologically evaluated. If it is a known mutagen like free BDDE, the manufacturer must prove that the residual levels in the final product are consistently below trace limits (often less than 2 parts per million, or ppm) to prevent chronic localized inflammatory responses.

Solvent Selection Mechanics

Extraction must utilize three distinct solvent types to ensure all potential leachables are captured:

1. Polar Solvents: Purified water or saline, simulating hydrophilic tissue environments.
2. Semi-polar Solvents: Ethanol or isopropyl alcohol, simulating lipid-water interfaces.
3. Non-polar Solvents: Hexane, simulating deep adipose tissue.

Skip any of these solvents, and you risk leaving fat-soluble or water-soluble impurities undetected, which is exactly how unverified fillers end up introducing toxic crosslinker residues into patients.

---

Legitimate Testing Timelines vs. Off-Brand Shortcuts

To understand why counterfeit and compounded injectables exist, one only needs to look at the time and cost required to complete legitimate biocompatibility testing.

According to data from Emergo by UL's biocompatibility testing workflows, a standard biocompatibility testing program for an implantable Class III device is highly time-consuming and expensive:

• Chemical Characterization (ISO 10993-18): Requires 3 to 6 weeks of instrument runtime and toxicological risk assessment.
• Cytotoxicity (ISO 10993-5): Requires 1 to 2 weeks.
• Sensitization (ISO 10993-10): Requires 6 to 8 weeks (including animal monitoring phases).
• Implantation (ISO 10993-6): Can require 3 to 12 months depending on the degradation timeline of the material.

The total cost for this suite of laboratory tests easily exceeds $150,000 to $300,000 per product formulation—excluding the cost of manufacturing clinical-grade test batches and compiling the regulatory submissions.

Case Study: Spiderwort CelluJuve Biocompatibility Gate

A real-world example of this regulatory gate is the development of CelluJuve, a novel cellulose-based dermal filler developed by Spiderwort.

As reported in Plastic Surgery Practice, before Health Canada or the U.S. FDA would authorize first-in-human clinical trials for this novel material, the manufacturer had to complete a full battery of ISO 10993 biocompatibility testing, followed by prospective human skin safety trials. Regulators do not allow shortcuts; if a material is going into human tissue, it must prove its safety profile in the laboratory first.

Compounded and off-brand suppliers bypass this entire testing process. They purchase bulk industrial-grade raw materials, package them in a sterile-looking syringe, and ship them directly to clinics. Because they skip the time, cost, and scrutiny of ISO 10993, they can sell their products at a fraction of the cost of legitimate fillers. However, the patient pays the price when their tissue reacts to the unverified chemistry.

---

FAQs: Clear Answers on Biocompatibility Regulations

Is an FDA-cleared filler automatically biocompatible?

Yes. An FDA clearance (via 510(k)) or approval (via PMA) is granted only after the FDA reviews the manufacturer's complete ISO 10993 biological evaluation report. If a device is legally cleared or approved by the FDA, it has passed all required biocompatibility testing for its cleared indications.

Why do biostimulators like Sculptra or Radiesse sometimes cause nodules if they passed ISO 10993?

Biocompatibility does not mean zero host response; it means an appropriate host response. Biostimulators work by triggering a mild, controlled foreign-body reaction to stimulate collagen. If the product is not reconstituted properly (e.g., if Sculptra is not diluted with enough sterile water or not allowed to hydrate fully), or if it is injected too superficially or in high concentrations, the body's inflammatory response can become overactive. This leads to mechanical nodules. These nodules are a technique and concentration complication, whereas nodules from counterfeit fillers are a chemical and toxicological failure.

Do PDO threads have to pass biocompatibility testing, and how long are they meant to stay in the body?

Yes. Lifting threads are classified as implantable devices in contact with tissue for longer than 30 days. They must pass ISO 10993 cytotoxicity, sensitization, irritation, genotoxicity, and implantation testing. PDO threads are designed to be absorbed by the body via hydrolysis over 6 to 9 months, but they must prove that their degradation products are non-toxic.

Are compounded or imported off-brand fillers tested to ISO 10993?

No. Compounded pharmacies and grey-market importers do not submit dossiers to the FDA or Notified Bodies. They do not perform chemical characterization (ISO 10993-18) or long-term animal implantation studies (ISO 10993-6) for their custom formulations. Consequently, their biocompatibility profile is completely unverified.

---

Sources

• International Organization for Standardization. (2018). ISO 10993-1:2018 Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. Retrieved from https://www.iso.org/standard/68702.html
• U.S. Food and Drug Administration. (2020). Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" — Guidance for Industry and Food and Drug Administration Staff. Retrieved from https://www.fda.gov/media/142959/download
• PureGlobal. (2026). ISO 10993 and ISO 14155 2026 Updates: Biocompatibility and Clinical GCP Standards. Retrieved from PureGlobal — ISO 10993 and ISO 14155 2026 updates
• PureGlobal. (2025). ISO 10993-1:2025 Biological Evaluation of Medical Devices - Edition 6 Update. Retrieved from PureGlobal — ISO 10993-1:2025 Edition 6 update
• Emergo by UL. (2023). ISO 10993-1 and Biocompatibility Whitepaper. Retrieved from https://www.emergobyul.com/sites/default/files/2023-08/PLC23CS1070961-ISO-Biocompatibility-Whitepaper_Final-Digital.pdf
• Plastic Surgery Practice. (2022). Health Canada Authorizes Clinical Trial for CelluJuve Dermal Filler. Retrieved from https://plasticsurgerypractice.com/client-objectives/rejuvenation/injectibles/health-canada-authorizes-clinical-trials-cellulose-based-dermal-filler
• U.S. Food and Drug Administration. (2026). Consensus Standards Database. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm